acute leukemia or myelodysplastic syndrome
Conditions
Interventions
Case series:chidamide+CAG+DLI
Sponsors
Chinese People's Liberation Army General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years male or female; 2. According to the 2008 WHO and 2017 NCCN guidelines, patients were diagnosed as relapse or high risk of acute leukemia or myelodysplastic syndrome after allogeneic stem cell transplantation; 3. ECOG score was 0-3; 4. The expected survival time of patients is more than 4 months. 5. Patients have ability to understand and be willing to sign the informed consent for clinical trial .
Exclusion criteria
Exclusion criteria: 1. Patients who were allergic or have contraindications to the drugs. 2. Patients were at pregnant and lactation period . 3. Patients with active infection. 4. Patients who smoked or indulge in excessive drinking , affected the outcome of the trial. 5. Patients with mental illness or other conditions, can not get informed consent, cooperate with treatment and physical examination. 6. Patients with active bleeding. 7. In the past year, patients have thrombosis, embolism, cerebral hemorrhage etc. 8. Patients were received surgical treatment ,and the operation period was less than 6 weeks. 9. Patients with clinically significant QTC interval prolongation ( time of male is more than 450ms, time of female is more than 470ms), ventricular tachycardia, atrial fibrillation, and above two degree cardiac block. Patients with myocardial infarction within 1 years, congestive heart failure, coronary artery heart with symptom and need to be treated. Patients with heart disease, the ultrasound showed that the area of the pericardial cavity was more than 10mm in the end diastole. 10. Patients with liver dysfunction, total bilirubin > 1.5 times normal upper limit, ALT/AST> 2.5 times normal upper limit. Patients with liver involvement, ALT/AST> 5 times normal upper limit. Patients with renal dysfunction, peripheral blood creatinine > 1.5 times normal upper limit; 11. Patients with II-IV graft-versus-host disease; 12. The researchers decided that participants were not suitable to participate in the clinical experiment .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission;partial remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival;overall survival; | — |
Countries
China
Contacts
Public ContactChunji Gao
Chinese People's Liberation Army General Hospital
Outcome results
None listed